Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  Apomorphine , 2020, Reactions Weekly.

[3]  D. Drapier,et al.  Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life , 2018, Journal of the Neurological Sciences.

[4]  G. Deuschl,et al.  Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial , 2018, The Lancet Neurology.

[5]  R. Iansek,et al.  Practical approaches to commencing device‐assisted therapies for Parkinson disease in Australia , 2017, Internal medicine journal.

[6]  Á. Sesar,et al.  Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients , 2017, Journal of Neurology.

[7]  F. Tamma,et al.  Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study , 2016, Neurological Sciences.

[8]  A. Lees,et al.  Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. , 2016, Parkinsonism & related disorders.

[9]  L. Defebvre,et al.  Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study , 2016, Journal of Neurology.

[10]  T. van Laar,et al.  Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. , 2016, Parkinsonism & related disorders.

[11]  A. Albanese,et al.  Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease , 2015, Neurology.

[12]  P. Svenningsson,et al.  EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[13]  J. C. Möller,et al.  Ropinirole-induced Pisa syndrome in Parkinson disease. , 2014, Clinical neuropharmacology.

[14]  Angelo Antonini,et al.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation , 2011, Journal of Neurology.

[15]  Y. Agid,et al.  Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[16]  I. Forgacs,et al.  Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. Piga,et al.  Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy , 2009, Journal of Neurology.

[18]  F. Stocchi.  Use of apomorphine in Parkinson’s disease , 2008, Neurological Sciences.

[19]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[20]  M. Canesi,et al.  Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease , 2008, Neurodegenerative Diseases.

[21]  S. Rehncrona,et al.  Multicenter study on deep brain stimulation in Parkinson's disease: An independent assessment of reported adverse events at 4 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[22]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[23]  M. Rudzińska,et al.  [Apomorphine in off state--clinical experience]. , 2007, Neurologia i neurochirurgia polska.

[24]  G. Deuschl,et al.  Deep brain stimulation: Postoperative issues , 2006, Movement disorders : official journal of the Movement Disorder Society.

[25]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  J. Brotchie.  Nondopaminergic mechanisms in levodopa‐induced dyskinesia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[27]  Mark Stacy,et al.  Apomorphine , 2004, Neurology.

[28]  A. Antonini,et al.  Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease , 2003, Neurological Sciences.

[29]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[30]  S. Giménez‐Roldán,et al.  [Use of apomorphine in Parkinson s disease]. , 2002, Revista de neurologia.

[31]  S. Factor,et al.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. , 2001, Archives of neurology.

[32]  A. Lees,et al.  Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. , 2001, Brain : a journal of neurology.

[33]  P. Odin,et al.  Apomorphine in the Treatment of Parkinson's Disease , 2001, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[34]  L. Vacca,et al.  Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results , 2001, Neurological Sciences.

[35]  A. Benabid,et al.  Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease , 2000, Neurology.

[36]  G K Wenning,et al.  Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[37]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[38]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[39]  A. Benabid,et al.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.

[40]  P. Leigh,et al.  Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. , 1997, Parkinsonism & related disorders.

[41]  E. Růžička,et al.  Apomorphine induced cognitive changes in Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[42]  A. Lees,et al.  SUBCUTANEOUS INFUSION OF APOMORPHINE AND LISURIDE IN THE TREATMENT OF PARKINSONIAN ON-OFF FLUCTUATIONS , 1987, The Lancet.

[43]  J. Péron,et al.  Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. , 2012, Parkinsonism & related disorders.

[44]  D. Deleu,et al.  Subcutaneous Apomorphine , 2004, Drugs & aging.

[45]  D. Deleu,et al.  Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease , 2002, Clinical pharmacokinetics.